Dr. Scott A. Irwin, MD

Dr. Irwin practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Irwin's NPI, 1225117716, was assigned on November 3, 2006. Dr. Irwin graduated from University of Illinois College of Medicine - Chicago in 2002. Dr. Irwin holds California license A84936.

Dr. Irwin's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Irwin's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. The medical group on file is Cedars-Sinai Medical Center. Dmand AI also links Dr. Irwin to 6 more medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Irwin practices, 3 sites in all. Vendor and product names are available with a free account.

Psychiatry is Dr. Irwin's primary specialty in the NPI Registry, under taxonomy code 2084P0800X. Dr. Irwin is board certified in consultation-liaison psychiatry by the American Board of Psychiatry and Neurology. Dr. Irwin is licensed in California.

Dmand AI lists adjustment disease, anxiety, depression and insomnia among the conditions Dr. Irwin treats.

CMS data shows 133 Medicare services from Dr. Irwin across 2 procedure codes in 2024, for 31 Medicare patients. Medicare paid $11,058 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 31 Medicare patients who saw Dr. Irwin in 2024. The largest group is 65 to 74, with 14 patients. 75% of them have anxiety, and 75% have cancer. Their average risk score is 2.37, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Irwin's median patient age at 67, with 57% women.

In 2024, Dr. Irwin wrote 260 Medicare Part D claims for 25 patients. 98% of them were for generic drugs. CMS names the drug for 215 of them, across 10 drugs with 11 or more claims each, at $3,403 in total drug cost. In 2023, CMS named 102 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Irwin for performance year 2024, reported as part of a group. Dr. Irwin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Irwin as offering telehealth.

Dmand AI links 82 papers to Dr. Irwin, published from 2008 to 2021. 2013 was the busiest year, with 7. The most frequent topics are Palliative Care, Hospice Care and California. Dr. Irwin has published most often in J Palliat Med. Dr. Irwin's most frequent co-authors are Jeremy Mason Hirst, MD, Nathan P. Fairman, MD and Dilip V. Jeste, MD.

Dmand AI links Dr. Irwin to 3 clinical trials, 2 of them early phase 1 studies. 1 is still active or recruiting. Conditions studied include Depression, Visceral Pain and Behavioral Symptoms. Cedars-Sinai Medical Center sponsors the most, 2.

CMS Open Payments shows 12 general payments to Dr. Irwin from 3 drug and device companies from 2018 to 2020. Food and beverage make up the largest share, 100% of the total. Sunovion Pharmaceuticals Inc. paid the most, $158.

Dmand AI lists 18 awards for Dr. Irwin, most recently Scholar in 2014.

Dr. Irwin graduated from University of Illinois College of Medicine - Chicago in 2002.

Dr. Irwin is in network with 9 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.